Canada Life
RGLS

Canada Life’s Regulus Therapeutics RGLS Stock Holding History

Canada Life’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-200
Closed -$79K – 2540
2016
Q3 		$79K Buy
+200
New +$82.3K ﹤0.01% 2225

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Canada Life's RGLS Position: Q4 2016 in Review

Canada Life sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 200 shares — an estimated $79K sold.

Canada Life first reported a position in RGLS in Q3 2016 and held it in 1 quarter. The position peaked at $79K in Q3 2016. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

  • Canada Life reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Canada Life sold 200 Regulus Therapeutics shares in Q4 2016, an estimated $79K.
  • Canada Life first reported a position in Regulus Therapeutics in Q3 2016 and held it in 1 quarter.
  • Canada Life's Regulus Therapeutics position peaked at $79K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on Canada Life's 13F filing for Q4 2016, filed 7 Feb 2017.